Victory Capital Management
OPNT

Victory Capital Management’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Victory Capital Management’s Portfolio OPNT Stock Details OPNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,348
Closed -$12K – 3511
2020
Q1 		$12K Buy
+1,348
New +$16.1K ﹤0.01% 3271
2019
Q4 		– Sell
-683
Closed -$10K – 3496
2019
Q3 		$10K Buy
+683
New +$9.52K ﹤0.01% 3279

Other funds holding OPNT

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FM
Fondren Management Houston, Texas $16.9M AUM 5.82% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
AIM
Alambic Investment Management Belvedere, California $9.12M AUM 34.54% 1-Year Est. Return

Victory Capital Management's OPNT Position: Q2 2020 in Review

Victory Capital Management sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q2 2020, closing a stake of 1,348 shares — an estimated $12K sold.

Victory Capital Management first reported a position in OPNT in Q3 2019 and held it in 2 quarters. The position peaked at $12K in Q1 2020. 30 funds tracked by Wall St. Rank hold OPNT as of Q2 2020.

  • Victory Capital Management reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 1,348 Opiant Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $12K.
  • Victory Capital Management first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $12K in Q1 2020.
  • 30 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.